<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3894">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04772703</url>
  </required_header>
  <id_info>
    <org_study_id>CVV_COVID-19_DNA</org_study_id>
    <nct_id>NCT04772703</nct_id>
  </id_info>
  <brief_title>DNA Damage in Critically Ill COVID-19 Patients</brief_title>
  <official_title>DNA Damage in Critically Ill Patients With SARS-CoV-2 Infection With Organ Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Hradec Kralove</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Hradec Kralove</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Critically ill patients with COVID-19 are exposed to high oxidative stress which is potential&#xD;
      harm to the DNA. Peripheral lymphocytes' DNA will be investigated using the comet assay on&#xD;
      changes in oxidative damage to the purine and pyrimidine bases and single-stranded DNA&#xD;
      breaks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data from hospital documentation will be recorded for all patients: demographic data,&#xD;
      clinical data (Horowitz index, the necessity of pronation position, opening maneuvers,&#xD;
      connection to ECMO, state of the circulation and other organ functions), laboratory data:&#xD;
      parameters of inflammatory activity and COVID-19 specific markers (blood count with&#xD;
      differential leukocyte count, CRP, IL-6, ferritin, procalcitonin, D-dimers).&#xD;
&#xD;
      In the study, 4 ml of heparinized peripheral blood will be collected for analytical purposes&#xD;
      beyond standard practice for lymphocyte isolation and monitoring of oxidative DNA damage upon&#xD;
      admission to the ICU (D1), after 2 days (D3) and on day 7 (D7) of the hospitalization. The&#xD;
      same blood sample will be used to determine EPA and DHA omega-3 in erythrocyte membranes. At&#xD;
      the same intervals and frequency, 10 ml of urine will be collected for the determination of&#xD;
      8-hydroxy-2-deoxyquanosine (8-OHdG), so a total of 30 ml of urine will be collected for&#xD;
      analytical purposes.&#xD;
&#xD;
      Details for analytical processing: peripheral blood lymphocyte damage will be assessed using&#xD;
      the alkaline COMET ASSAY method for DNA breakage and modified COMET ASSAY using specific&#xD;
      enzymes for the detection of oxidized bases, endonuclease III (ENDO III) for the detection of&#xD;
      oxidized pyrimidines and formamidopyrimidine DNA glycosylase (FPG) for the detection of&#xD;
      oxidized purines. Leukocyte repair capacity will be determined using a modified COMET ASSAY,&#xD;
      which uses extracts of patient lymphocytes and HeLa cells with defined DNA damage. The extent&#xD;
      of 8-hydroxy-2-deoxyquanosine (8-OHdG) DNA damage in patients' urine will be determined by&#xD;
      determining the concentration of 8-OHdG by ELISA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>single-stranded DNA breaks</measure>
    <time_frame>One week</time_frame>
    <description>Changes in the single-stranded DNA breaks in peripheral lymphocytes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oxidation of DNA bases</measure>
    <time_frame>One week</time_frame>
    <description>Changes in oxidised purine and pyrimidine bases of peripheral lymphocytes DNA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>One month</time_frame>
    <description>All cause 30-day mortality</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Covid19</condition>
  <condition>Organ Failure, Multiple</condition>
  <condition>DNA Damage</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>COMET ASSAY</intervention_name>
    <description>The description in the detailed description of the study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients admitted to ICU with signs and symptoms of organ failure, mainly&#xD;
        respiratory failure. Need for means of respiratory and/or circulatory support. A positive&#xD;
        test of COVID-19: RT-PCR test or bed-side antigen test.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  critically ill adult patient admitted to ICU with positive RT-PCR test or bed-side&#xD;
             antigen test on COVID-19 with signs and symptoms of organ failure&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  rejection by the patient to sign an informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zdeněk Zadák, prof., M.D., Ph.D.</last_name>
    <phone>+420495832166</phone>
    <email>zadak@fnhk.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Astapenko, M.D., Ph.D.</last_name>
    <phone>+420495833218</phone>
    <email>david.astapenko@fnhk.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Hradec Kralove</name>
      <address>
        <city>Hradec Králové</city>
        <state>Třebeš</state>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Dostal, M.D., Ph.D., MBA</last_name>
      <phone>+420495833218</phone>
      <email>karim@fnhk.cz</email>
    </contact>
    <contact_backup>
      <last_name>David Astapenko, M.D., Ph.D.</last_name>
      <phone>+420495833218</phone>
      <email>david.astapneko@fnhk.cz</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Organ Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

